Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy

2.50
Hdl Handle:
http://hdl.handle.net/10755/308158
Category:
Abstract
Type:
Presentation
Title:
Breast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapy
Author(s):
Dahir, Melissa A.
Lead Author STTI Affiliation:
Iota Tau
Author Details:
Melissa A. Dahir, MSN, NP-C, IF, mdahir@me.com
Abstract:

Poster presented on: Sunday, November 17, 2013, Saturday, November 16, 2013

The purpose of the pilot study is to evaluate the effects of using a daily testosterone 0.3% vaginal cream on the reported vulvovaginal symptoms and sexual health quality of life in women with breast cancer who are taking aromatase inhibitors (AIs). The research questions addressed in the pilot project are:  does daily application of topical vaginal testosterone cream by women with breast cancer and who are taking AIs (1) reduce reported vulvovaginal symptoms and/or (2) improve sexual health quality of life as measured by the Female Sexual Function Index (FSFI) questionnaire?

At the present time, there are no Food and Drug Administration (FDA) approved medications for the vulvovaginal or sexual side effects related to the use of AIs. The lack of treatment options is concerning because the number of women diagnosed with breast cancer continues to increase; their longevity, also, continues to increase with the use of newer adjuvant chemotherapies. At the present time, there is limited research regarding the safety and efficacy of using local vaginal hormones to alleviate symptoms associated with AI treatment.

The quasi-experimental study involves a one group pre-posttest design. A non-probability convenience sample of 10 to 20 participants from an oncology clinic will be enrolled in the study. At the first study visit, the research nurse practitioner will collect patient demographic information, perform a physical examination, and procure a vaginal culture. The FSFI questionnaire will be administered at the initial visit and re-administered after four weeks of using the study drug. Statistical analyses of the pretest and posttest scores will determine if using a compounded testosterone vaginal cream daily for four weeks produces a statistically significant effect on sexual health functioning and vulvovaginal symptoms as reported by women with breast cancer taking AI therapy.

Keywords:
breast cancer; sexual health; vaginal testosterone
Repository Posting Date:
19-Dec-2013
Date of Publication:
19-Dec-2013
Conference Date:
2013
Conference Name:
42nd Biennial Convention
Conference Host:
Sigma Theta Tau International, the Honor Society of Nursing
Conference Location:
Indianapolis, Indiana, USA
Description:
42nd Biennial Convention 2013 Theme: Give Back to Move Forward. Held at the JW Marriott
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission.

Full metadata record

DC FieldValue Language
dc.language.isoen_USen_GB
dc.type.categoryAbstracten_GB
dc.typePresentationen_GB
dc.titleBreast Cancer, Aromatase Inhibitor Therapy, and Sexual Functioning: A Pilot Study on the Effects of Vaginal Testosterone Therapyen_GB
dc.contributor.authorDahir, Melissa A.en_GB
dc.contributor.departmentIota Tauen_GB
dc.author.detailsMelissa A. Dahir, MSN, NP-C, IF, mdahir@me.comen_GB
dc.identifier.urihttp://hdl.handle.net/10755/308158-
dc.description.abstract<p>Poster presented on: Sunday, November 17, 2013, Saturday, November 16, 2013</p>The purpose of the pilot study is to evaluate the effects of using a daily testosterone 0.3% vaginal cream on the reported vulvovaginal symptoms and sexual health quality of life in women with breast cancer who are taking aromatase inhibitors (AIs). The research questions addressed in the pilot project are:  does daily application of topical vaginal testosterone cream by women with breast cancer and who are taking AIs (1) reduce reported vulvovaginal symptoms and/or (2) improve sexual health quality of life as measured by the Female Sexual Function Index (FSFI) questionnaire? <p>At the present time, there are no Food and Drug Administration (FDA) approved medications for the vulvovaginal or sexual side effects related to the use of AIs. The lack of treatment options is concerning because the number of women diagnosed with breast cancer continues to increase; their longevity, also, continues to increase with the use of newer adjuvant chemotherapies. At the present time, there is limited research regarding the safety and efficacy of using local vaginal hormones to alleviate symptoms associated with AI treatment. <p>The quasi-experimental study involves a one group pre-posttest design. A non-probability convenience sample of 10 to 20 participants from an oncology clinic will be enrolled in the study. At the first study visit, the research nurse practitioner will collect patient demographic information, perform a physical examination, and procure a vaginal culture. The FSFI questionnaire will be administered at the initial visit and re-administered after four weeks of using the study drug. Statistical analyses of the pretest and posttest scores will determine if using a compounded testosterone vaginal cream daily for four weeks produces a statistically significant effect on sexual health functioning and vulvovaginal symptoms as reported by women with breast cancer taking AI therapy.en_GB
dc.subjectbreast canceren_GB
dc.subjectsexual healthen_GB
dc.subjectvaginal testosteroneen_GB
dc.date.available2013-12-19T17:27:39Z-
dc.date.issued2013-12-19-
dc.date.accessioned2013-12-19T17:27:39Z-
dc.conference.date2013en_GB
dc.conference.name42nd Biennial Conventionen_GB
dc.conference.hostSigma Theta Tau International, the Honor Society of Nursingen_GB
dc.conference.locationIndianapolis, Indiana, USAen_GB
dc.description42nd Biennial Convention 2013 Theme: Give Back to Move Forward. Held at the JW Marriotten_GB
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission.en_GB
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.